Epstein Files Search

EFTA01092032Set 9

25p12,760w

Validated industrial scale CD34+ GCSF derrived Adult Autologous adult production, Baxter Messenchymal stem peripheral Phase Ill trial in CMI cells, High COGS millions of doses cells blood of cells from ... expanded on-site in 60 Adherrent stromal cells Adipose Autologous adult minutes or less, Phase Ill trial in STEMI. Cytori (ASC) derived from tissue cells, Low COGS minimal Phase ... enriched for CD34+CXCR4+ cells cells from a single Single Allogeneic- donation can be Phase Ill in steroid Donor, universal expanded to Osiris MSC expanded ex-vivo refractory GvHD. Expanded

https://www.justice.gov/epstein/files/DataSet%209/EFTA01092032.pdf

EFTA01369707Set 10

1p181w

investors I Pre-acquisition, the SPAC Phase I - Pre-acquisition Phase II — At acquisition Phase Ill — Post-acquisition trades like a zero coupon Bond-floor + call option Bond-floor + equity

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01369707.pdf

EFTA02714282Set 11

8p3,952w

PrechnIcal Phase I Phase II Phase III APPROVEC Launched by Spectrum Pilorm. in 3Q13 PhaSe ill trial started in 4C113 Phasell testingin China in 2H13 Marqibo, is a liposomal formulation

https://www.justice.gov/epstein/files/DataSet%2011/EFTA02714282.pdf

EFTA01113072Set 9

2012-11-203p1,137w

treatment of reperfusion injuries following stenting. CicloMulsion° is currently in a 1000 patient Phase Ill clinical trial evaluating its ability to reduce reperfusion injuries in patients with myocardial infarction. NeuroVive

https://www.justice.gov/epstein/files/DataSet%209/EFTA01113072.pdf

EFTA00589347Set 9

2012-11-203p1,134w

treatment of reperfusion injuries following stenting. CicloMulsion° is currently in a 1000 patient Phase Ill clinical trial evaluating its ability to reduce reperfusion injuries in patients with myocardial infarction. NeuroVive

https://www.justice.gov/epstein/files/DataSet%209/EFTA00589347.pdf

EFTA02128952Set 10

2013-09-057p1,749w

sells ElectroWorld & Pixmania (trading +8.5%) • Glaxo: MAGE-A3 fails first co-primary endpoint in Phase Ill melanoma clinical trial (trading -1.4%) • SKF agrees to buy Kaydon for $35.50 per share

https://www.justice.gov/epstein/files/DataSet%2010/EFTA02128952.pdf

EFTA00283681Set 9

6p1,894w

typical distinctive feature for Alzheimer, have not yet resulted in any positive results in phase ill clinical trials. 3 EFTA00283683 Short description of the division "Karolinska Institutet Alzheimer Disease Research

https://www.justice.gov/epstein/files/DataSet%209/EFTA00283681.pdf

EFTA01113739Set 9

37p2,922w

Xalkory® registered in ALK+ NSCLC pts (3-5% NSCLC pts) OSE EFTA01113747 OSE 2101:Phase Ill Protocol & Objectives HLA A2 NSCLC population, open, randomized, multi-center comparative study: 500pts ■ Versus

https://www.justice.gov/epstein/files/DataSet%209/EFTA01113739.pdf

EFTA01457560Set 10

1p219w

decision in severe asthma 2015 Mosquirix EMA approval decision on malaria vaccine 2015 Sartakumab Phase Ill data in rheumatoid arthritis IRA) 2015 Investigation Possible outcome of SFO investigation 2/115 HZ/su

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01457560.pdf

EFTA01583194Set 10

1p526w

cunt/nen or oar:mingled reporting account) on tnit Icon When adding margin accounts, the Phase Ill or MACS account number is noosed. Du each irsfividual occurs nurreor oral adtatonal services

https://www.justice.gov/epstein/files/DataSet%2010/EFTA01583194.pdf